Coyote Bioscience

Executive Summary

Coyote Bioscience, a private Chinese biotechnology company founded in 2012, specializes in molecular diagnostics and point-of-care testing for infectious diseases. Leveraging its proprietary nucleic acid amplification platform, the company develops rapid, accessible diagnostic solutions that address critical gaps in clinical testing speed and accessibility, particularly for infectious disease management. With a workforce of 200–500 employees and a commercial-stage portfolio, Coyote focuses on bringing decentralized testing to clinical settings, thereby reducing turnaround times and improving patient outcomes. The company's technology is well-suited for both hospital and remote settings, aligning with global trends toward faster, more convenient diagnostics. While specific financial details and revenue figures are not public, Coyote's established presence and ongoing product development suggest a solid footing in the competitive molecular diagnostics landscape, which is projected to grow as demand for rapid testing persists post-pandemic. The company competes with larger international players but differentiates through its China-based R&D and manufacturing base, allowing for cost-effective production and potential price advantages in emerging markets. Given its focus on infectious diseases and point-of-care platforms, Coyote is well-positioned to capture market share in regions underserved by traditional lab-based diagnostics.

Upcoming Catalysts (preview)

• Q4 2026Launch of next-generation point-of-care PCR platform70% success
• H1 2027Regulatory approval for tuberculosis diagnostic test in China60% success
• 2026-2027Partnership with WHO or global health initiative for infectious disease screening50% success